#co-pay

During the COVID-19 crisis, some insurers are relaxing their refill rules and allowing 90-day supplies of meds to be prescribed.

Over 60 drugmakers raised prices an average of 5.8% on hundreds of drugs.

Only one company will sell a version of the HIV prevention pill Truvada. When others go to market, prices will likely drop further.

Insurance companies can no longer implement harmful co-pay accumulator policies.

Pharma sets the prices for HIV and hep C drugs very high. What happens to those prices along the supply chain?

Stop me if you’ve heard this one before.

The patient advocacy coalition I Am Essential sent a letter to the HHS spelling out why the plan is dangerous.

Health coalition warns the federal government: People with chronic or serious conditions face growing costs at the pharmacy.

Among other issues: Out-of-pocket costs are increasingly passed on to consumers.

60 groups sign a letter to state insurance commissioners and attorneys general asking them to reverse the policy.

My fear of the dentist was setting me up for a future of teeth loss.

In summary: Bandage it or blow it up?

ViiV Healthcare, which makes several antiretroviral (ARV) drugs, is expanding programs to help HIV-positive people access the company’s...

Gilead Sciences and Bristol-Myers Squibb have announced that the co-payment assistance program for Atripla (containing efavirenz...